Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom

Aclidinium bromide is an inhaled long-acting muscarinic antagonist (LAMA). Although the initial potential increased cardiovascular and mortality risk among users of tiotropium has been ruled out by several observational studies, and clinical trials, there are still concerns related to the use of newer LAMA medications. The current study aimed to evaluate the risk of death among users of aclidinium and other LAMAs.

Source: Respiratory Medicine - April 25, 2019 Category: Respiratory Medicine Authors: Cristina Rebordosa, Jaume Aguado, Estel Plana, Steven Thomas, Ana Frances, Alejhandra Lei, Esther Garc ía-Gil, Javier Nuevo, Susana Perez-Gutthann, Jordi Castellsague Source Type: research